Targeted therapies for cancer

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

(2022) Zihua Zou et al.   BMC Medicine

Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy

(2022) Justyna Mączyńska et al.   BMC Medicine

The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy

(2021) Sreeram Ramagopalan et al.   BMC Medicine

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

(2021) Yongchang Zhang et al.   BMC Medicine

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer

(2021) Jiao Hu et al.   BMC Medicine

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer

(2021) Shen Zhao et al.   BMC Medicine

m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

(2021) Zhihui Zhang et al.   BMC Medicine

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

(2021) Yongchang Zhang et al.   BMC Medicine

Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

(2021) Denise Müller et al.   BMC Medicine